CDK9 and acute myeloid leukemia: There is sufficient evidence that supports the role of CDK9 as a molecular target for treatment of a number of malignancies including breast cancer, colorectal cancer, and acute myeloid leukaemia (AML) [4,5,6,7,8,9].